MN

Marian Nakada

Using BIG for GOOD. Making strategic investments for Johnson & Johnson Innovation - JJDC

Cambridge, Massachusetts

Invests in

Stages:

  • Min Investment:

    $0.00
  • Max Investment:

    $0.00
  • Target Investment:

    $0.00

Education

Work Experience

  • Board Observer

    2024

  • Vice President, Venture Investments JJDC

    2013

    Focuses on pharmaceutical venture investments on the East Coast, in support of Janssen R&D objectives. Works closely with Boston Innovation Center colleagues, Therapeutic Areas and cross-R&D Functional Areas.

  • Advisor

    2019

    Provide input to shape the themes, topics and speakers for the Convergence Forum

  • Member

    2021

  • Board Observer

    2021

  • Board Member

    2020

  • Board Chair

    2019 - 2020

  • Board Member

    2013

  • Board Member

    2016 - 2023

    The NEVCA fosters a collaborative, inclusive, and prosperous innovation ecosystem on behalf of New England's VC industry. Operating across four pillars - Venture Community, Regional Brand, Workforce Development, and Public Policy - the association's initiatives impact the community at large: events connect founders, funders, and innovators; legislative advocacy promotes economic growth; programs bolster professional development across the venture landscape.

  • Board Member

    2018 - 2023

    Twentyeight-Seven Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.

  • Board Observer

    2014 - 2021